Frequently Asked Questions
North America dominates the API contract manufacturing market due to the presence of high healthcare expenditure and rising requirement for new bio-generic drugs.
The growth rate of the API contract manufacturing market is 9.90%.
Technological advancement in production of API & high demand for novel bio-generic drugs are the growth drivers of the API contract manufacturing market.
Type, volume, form end-users and distribution channel are the factors on which the API contract manufacturing market research is based.
Major companies in the API contract manufacturing market are Teva Pharmaceuticals Industries Ltd, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Piramal Pharma Solutions, Sandoz AG, GlaxoSmithKline Plc., Lupin, and Juniper Pharmaceutical among other domestic and global players
